Free Trial
TSE:SVA

Sernova Q3 2024 Earnings Report

Sernova logo
C$0.21 -0.01 (-4.55%)
As of 10:16 AM Eastern

Sernova EPS Results

Actual EPS
-C$0.02
Consensus EPS
-C$0.03
Beat/Miss
Beat by +C$0.01
One Year Ago EPS
N/A

Sernova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Sunday, September 15, 2024
Conference Call Time
8:00PM ET

Earnings Documents

Sernova Earnings Headlines

Sernova Biotherapeutics Inc (SVA.TO)
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.
Jobs Reports Due for Next Week
See More Sernova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova and other key companies, straight to your email.

About Sernova

Sernova (TSE:SVA) Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.

View Sernova Profile

More Earnings Resources from MarketBeat